AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Bladder Cancer at ASCO 2026: A New Standard in Non-Muscle Invasive Disease, Intravesical Approaches in Muscle-Invasive Disease, and Three and a Half Years of Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
Bladder Cancer at ASCO 2026: A New Standard in Non-Muscle Invasive Disease, Intravesical Approaches in Muscle-Invasive Disease, and Three and a Half Years of Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
Bladder Cancer at ASCO 2026: A New Standard in Non-Muscle Invasive Disease, Intravesical Approaches in Muscle-Invasive Disease, and Three and a Half Years of Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.